Navigation Links
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced that data for romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL. The data presented are part of an interim analysis of a phase II study of romidepsin sponsored by the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Gloucester.

Data from the NCI's ongoing clinical trial of romidepsin was presented in Abstract #8027 "Phase II Trial of Depsipeptide in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma" on Monday, June 4th.

The interim results reported on 70 patients with CTCL and 39 patients with PTCL. In the CTCL patient group 4 of 70 patients, or 6%, achieved a complete response, with the duration of response ranging from 8 to 63+ months. A partial response was observed in 18 of 70 patients, or 26%, with the duration of response ranging from 1 to 69+ months. The most common adverse events reported were nausea, vomiting, fatigue, transient granulocytopenia and thrombocytopenia, and anorexia.

Commenting on the data from the NCI's study, William McCulloch, M.B., FRCP, Executive Vice President and Chief Medical Officer at Gloucester said, "Clinical evidence for romidepsin's value in the treatment of T-cell lymphomas continues to build. Based on the data from this trial, as well as interim data from our own Gloucester-sponsored CTCL pivotal phase II study which is nearing completion, we remain enthusiastic about the clinical prospects for romidepsin."

In the PTCL patient group 3 of 39 patients, or 7%, achieved a complete response, with the duration of response ranging from 9 to 43+ months. A partial respons e was observed in 8 of 39 patients, or 21%, with the duration of response ranging from 2 to 16+ months. The most common adverse events reported were nausea, vomiting, fatigue, transient granulocytopenia and thrombocytopenia, and anorexia.

"We are impressed about the durability of responses, including both CRs and PRs, that have been seen in the PTCL patients thus far." said Jean Nichols, Ph.D., Executive Vice President and Chief Scientific Officer at Gloucester. "Based on the positive data from this study, we recently commenced a multinational pivotal phase II study of romidepsin in PTCL patients who have relapsed or become refractory following systemic therapy," she concluded.

About CTCL

CTCL is a group of diseases, including Mycosis Fungoides and Sezary syndrome, all constituting types of non-Hodgkin's lymphoma in which certain cells of the lymph system (T-cells) become cancerous and affect the skin. The disorder is characterized by abnormal accumulation of malignant T-cells in the skin, which result in the development of itchy rashes, plaques and tumors. Occasionally malignant cells can be found circulating in the bloodstream and visceral (internal organ) involvement can occur. Symptoms of the disorder often include pruritus, an intense itching sensation, which leads to scratching that may cause breaks in the skin that lead to infection. In some patients, pruritus can be so severe that it affects overall quality of life. There are about 40,000 CTCL patients worldwide.

About PTCL

Peripheral T-cell lymphoma is a term which encompasses a number of different malignancies of T-cell origin that account for about 10-15% of all cases of non-Hodgkin's lymphoma. PTCL can occur at any age from young adulthood to old age and is slightly more common in men than in women. It is a particularly aggressive form of lymphoma with a short median duration of life expectancy (approximately two years) from diagnosis.

About Romidepsin

Rom idepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which includes CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan Drug status for the treatment of both CTCL and PTCL. Fast Track status for CTCL and PTCL has also been designated by the FDA. Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com or call 888-GPI-CTCL (888-474-2825).

Contact

Media:
KmorrisPR
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com
or
Gloucester Pharmaceuticals
Beverly Holley, 617-583-1362 or 781-235-9803
beverly@gloucesterpharma.com


'"/>




Related medicine technology :

1. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
2. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):